

(ii) modifying said human cell line by introducing into said human cell line a nucleic acid molecule comprising a nucleic acid sequence encoding GM-CSF operably linked to a promoter and a nucleic acid sequence encoding a selectable marker operably linked to a promoter; and

(iii) using the selectable marker to isolate cells that produce about 500 ng or greater of said GM-CSF/10⁶ cells/24 hours.

24. The method of claim 23, wherein the modified human cell line is cultured in culture medium comprising about 400 µg or greater hygromycin/ml culture medium.

25. The method of claim 24, wherein the modified human cell line is subsequently cultured in culture medium comprising about 1,000 µg or greater hygromycin/ml culture medium.

REMARKS


The specification has been amended at page 20, line 12, to change Fig. 4 to Fig. 1. This amendment corrects an obvious error in Example 2. Fig. 4 clearly does not show subclones of GM-CSF-producing K562 cells that produced in excess of 1,000 ng/10⁶ cells/24 hours. Rather, Fig. 4 clearly presents a graph of percent tumor-free survival versus days post-tumor challenge. Because Fig. 1 shows GM-CSF-producing K562 cells that produced in excess of 1,000 ng/10⁶ cells/24 hrs, Fig. 1 should be referenced in Example 2 at page 20, line 12, rather than Fig. 4. Because this amendment merely corrects an obvious error, this amendment has added no new subject matter to the specification.

The claims have been amended in view of the restriction requirement in the parent application. In addition, claims 1, 5, 8, 11-14 and 22-25 have been amended to point out more particularly and claim more distinctly the present invention by changing the phrase "at least about" to "about...or greater." No new matter has been added by way of these amendments.

In re Appln. of Levitsky et al.
Application No. Unassigned

The application is considered to be in good and proper form for allowance and the Examiner is respectfully requested to pass this application to issuance. If, in the opinion of the Examiner, a telephone conference would expedite the examination of this application, the Examiner is invited to contact the undersigned attorney.

Respectfully submitted,



Carol Larcher, Reg. No. 35,243
One of the Attorneys for Applicants
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: November 16, 2001

m:\clients\Hopkins\amd\213026preamd

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Levitsky et al.

Application No. Unassigned

Filed: November 16, 2001

Art Unit: Unassigned

Examiner: Unassigned

For: A UNIVERSAL
IMMUNOMODULATORY CYTOKINE-
EXPRESSING BYSTANDER CELL
LINE AND RELATED COMPOSITIONS
AND METHODS OF MANUFACTURE
AND USE

AMENDMENTS TO SPECIFICATION AND CLAIMS
MADE VIA PRELIMINARY AMENDMENT

Amendments to the paragraph beginning at page 20, line 12:

As shown in [Fig. 4] Fig. 1, subclones of GM-CSF-producing K562 cells produced in excess of 1,000 ng/10⁶ cells/24 hrs. The use of such subclones enables the use of as few as one bystander cell per 10 autologous tumor cells with a clear margin of safety above the GM-CSF threshold of 36 ng GM-CSF/10⁶ cells/24 hrs, by targeting 100 ng/10⁶ cells/24 hrs.

Amendments to existing claims:

Claims 15, 16, 29-39, 48 and 49 have been canceled.

The indicated claims have been amended as follows:

1. (Amended) A universal bystander cell line, which:
 - (i) is a human cell line,
 - (ii) naturally lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens [or is modified so that it lacks MHC-I antigens and MHC-II antigens], and
 - (iii) is modified by introduction of a nucleic acid molecule comprising a nucleic acid sequence encoding granulocyte macrophage-colony stimulating factor (GM-CSF) operably linked to a promoter,wherein said universal bystander cell line expresses [at least] about 500 ng or greater GM-CSF/10⁶ cells/24 hours.

5. (Amended) The universal bystander cell line of claim 1, which expresses [at least] about 1,000 ng or greater GM-CSF/10⁶ cells/24 hours.

8. (Amended) The universal bystander cell line of claim 4, which expresses [at least] about 1,000 ng or greater GM-CSF/10⁶ cells/24 hours.

11. (Amended) The universal bystander cell line of claim 1, wherein said nucleic acid molecule further comprises a nucleic acid sequence encoding hygromycin resistance operably linked to a promoter and said universal bystander cell line is selected by growth in a culture medium comprising [at least] about 400 µg/ml or greater hygromycin.

12. (Amended) The universal bystander cell line of claim 11, wherein said universal bystander cell line is selected by growth in a culture medium comprising [at least] about 1,000 µg/ml or greater hygromycin.

13. (Amended) The universal bystander cell line of claim 4, wherein said nucleic acid molecule further comprises a nucleic acid sequence encoding hygromycin resistance operably linked to a promoter and said universal bystander cell line is selected by growth in a culture medium comprising [at least] about 400 µg/ml or greater hygromycin.

14. (Amended) The universal bystander cell line of claim 13, wherein said universal bystander cell line is selected by growth in a culture medium comprising [at least] about 1,000 µg/ml or greater hygromycin.

22. (Amended) A method of making a universal GM-CSF-expressing bystander cell line, which method comprises:

- (i) obtaining a human cell line that lacks MHC-I antigens and MHC-II antigens;
- (ii) modifying said human cell line by introducing into said human cell line a nucleic acid molecule comprising a nucleic acid sequence encoding GM-CSF operably linked to a promoter and a nucleic acid sequence encoding a selectable marker operably linked to a promoter; and
- (iii) using the selectable marker to isolate cells that produce [at least] about 500 ng or greater of said GM-CSF/10⁶ cells/24 hours.

24. (Amended) The method of claim 23, wherein the modified human cell line is cultured in culture medium comprising [at least] about 400 μg or greater hygromycin/ml culture medium.

25. (Amended) The method of claim 24, wherein the modified human cell line is subsequently cultured in culture medium comprising [at least] about 1,000 μg or greater hygromycin/ml culture medium.